Center for Cancer Biology Research

癌症生物学研究中心

基本信息

  • 批准号:
    8486454
  • 负责人:
  • 金额:
    $ 217.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-02 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

This is a proposal to establish a Center of Biomedical Research Excellence (COBRE) focusing on Cancer Biology with emphasis on the identification, functional characterization, and targeting of tumor specific markers and antigens. Our center will use cell and molecular biology, immunology, nanoparticle technology, and animal models to examine the development, detection, and treatment of human cancer. Five research projects are included. The goals of Project 1 (Meena Jaggi, PhD) are to understand the effects of protein kinase Dl on (3- catenin-mediated signaling and to determine if PKD1 expression influences tumor progression through this pathway. For Project 2 (Kristi Egland, PhD) a large number of membrane and secreted proteins that are expressed at elevated levels in prostate cancer cells were identified. This information will be used to develop a new diagnostic test for prostate cancer that detects autoantibodies in patient serum. Project 3 (Satoshi Nagata, PhD) will develop a panel of monoclonal antibodies to surface antigens that are highly expressed in B cell malignancies. These antibodies will be tested for their potential use in immunotherapies. Project 4 (Subhash Chauhan, PhD) will develop novel methods of treatment and drug delivery for pancreatic cancer. The goal will be to combine radioimmunotherapy and nanoparticle technology for highly specific delivery of cytotoxic compounds. Project 5 (William Spanos, MD) will focus on the role of the immune response in tumor clearance following treatment of head and neck squamous cell carcinoma. A strong mentoring plan will take advantage of the experience of an outstanding group of senior faculty with active research programs. Mentors will provide guidance for research design, manuscript preparation, grant applications, and other crucial aspects of career development. An EAC consisting of five internationally recognized scientists with broad experience in basic, translational, and clinical research has been assembled. Research capabilities will be supported by core facilities in Molecular Pathology, Flow Cytometry, Tumor Biology, and Imaging. We will recruit 3 high quality junior investigators and 1 established investigator. We will train students and post-doctoral fellows, support a seminar series, and fund pilot research projects in the field of cancer research.
这是一个建立生物医学研究卓越中心(COBRE)的建议,重点是癌症生物学,重点是肿瘤特异性标志物和抗原的识别,功能表征和靶向。我们的中心将使用细胞和分子生物学,免疫学,纳米粒子技术和动物模型来研究人类癌症的发展,检测和治疗。包括五个研究项目。项目1(Meena Jaggi,PhD)的目标是了解蛋白激酶D1对β-连环蛋白介导的信号传导的影响,并确定PKD 1表达是否通过该途径影响肿瘤进展。对于项目2(Kristi Egland,PhD),鉴定了在前列腺癌细胞中以升高水平表达的大量膜和分泌蛋白。这些信息将用于开发一种新的前列腺癌诊断测试,检测患者血清中的自身抗体。项目3(Satoshi Nagata,PhD)将开发一组针对B细胞恶性肿瘤中高度表达的表面抗原的单克隆抗体。将测试这些抗体在免疫疗法中的潜在用途。项目4(Subhash Chauhan博士)将开发胰腺癌治疗和药物输送的新方法。目标将是结合联合收割机放射免疫治疗和纳米颗粒技术,高度特异性地传递细胞毒性化合物。项目5(William Spanos,MD)将重点关注头颈部鳞状细胞癌治疗后免疫应答在肿瘤清除中的作用。一个强有力的指导计划将利用一组优秀的高级教师的经验,积极的研究计划。导师将为研究设计,手稿准备,资助申请和职业发展的其他关键方面提供指导。EAC由五位国际公认的科学家组成,他们在基础,转化和临床研究方面具有广泛的经验。研究能力将得到分子病理学,流式细胞术,肿瘤生物学和成像的核心设施的支持。我们将招募3名高素质的初级研究者和1名资深研究者。我们将培训学生和博士后研究员,支持一系列研讨会,并资助癌症研究领域的试点研究项目。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

W KEITH MISKIMINS其他文献

W KEITH MISKIMINS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('W KEITH MISKIMINS', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10628879
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
Pilot Project Program
试点项目计划
  • 批准号:
    10628882
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
Center for Cancer Biology Research
癌症生物学研究中心
  • 批准号:
    10628878
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
(PQA1)Molecular mechanisms by which the diabetic drug metformin kills cancer cell
(PQA1)糖尿病药物二甲双胍杀死癌细胞的分子机制
  • 批准号:
    8712424
  • 财政年份:
    2013
  • 资助金额:
    $ 217.09万
  • 项目类别:
(PQA1)Molecular mechanisms by which the diabetic drug metformin kills cancer cell
(PQA1)糖尿病药物二甲双胍杀死癌细胞的分子机制
  • 批准号:
    8858397
  • 财政年份:
    2013
  • 资助金额:
    $ 217.09万
  • 项目类别:
(PQA1)Molecular mechanisms by which the diabetic drug metformin kills cancer cell
(PQA1)糖尿病药物二甲双胍杀死癌细胞的分子机制
  • 批准号:
    8590394
  • 财政年份:
    2013
  • 资助金额:
    $ 217.09万
  • 项目类别:
(PQA1)Molecular mechanisms by which the diabetic drug metformin kills cancer cell
(PQA1)糖尿病药物二甲双胍杀死癌细胞的分子机制
  • 批准号:
    9063480
  • 财政年份:
    2013
  • 资助金额:
    $ 217.09万
  • 项目类别:
CENTER FOR CANCER BIOLOGY RESEARCH
癌症生物学研究中心
  • 批准号:
    8359559
  • 财政年份:
    2011
  • 资助金额:
    $ 217.09万
  • 项目类别:
Center for Cancer Biology Research
癌症生物学研究中心
  • 批准号:
    8707495
  • 财政年份:
    2011
  • 资助金额:
    $ 217.09万
  • 项目类别:
Center for Cancer Biology Research
癌症生物学研究中心
  • 批准号:
    8898842
  • 财政年份:
    2011
  • 资助金额:
    $ 217.09万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 217.09万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 217.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了